- Home
- IOVA vs PRME Comparison
IOVA vs PRME Comparison
Compare IOVA & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- PRME
- Stock Information
- Founded
- IOVA 2007
- PRME 2019
- Country
- IOVA United States
- PRME United States
- Employees
- IOVA N/A
- PRME N/A
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- PRME Medicinal Chemicals and Botanical Products
- Sector
- IOVA Health Care
- PRME Health Care
- Exchange
- IOVA Nasdaq
- PRME Nasdaq
- Market Cap
- IOVA 1.0B
- PRME N/A
- IPO Year
- IOVA N/A
- PRME 2022
- Fundamental
- Price
- IOVA $3.17
- PRME $1.34
- Analyst Decision
- IOVA Strong Buy
- PRME Strong Buy
- Analyst Count
- IOVA 9
- PRME 6
- Target Price
- IOVA $18.22
- PRME $13.17
- AVG Volume (30 Days)
- IOVA 9.3M
- PRME 1.5M
- Earning Date
- IOVA 05-08-2025
- PRME 05-08-2025
- Dividend Yield
- IOVA N/A
- PRME N/A
- EPS Growth
- IOVA N/A
- PRME N/A
- EPS
- IOVA N/A
- PRME N/A
- Revenue
- IOVA $164,070,000.00
- PRME $3,846,000.00
- Revenue This Year
- IOVA $182.20
- PRME $56.92
- Revenue Next Year
- IOVA $62.10
- PRME $150.59
- P/E Ratio
- IOVA N/A
- PRME N/A
- Revenue Growth
- IOVA 13698.99
- PRME 550.76
- 52 Week Low
- IOVA $2.70
- PRME $1.12
- 52 Week High
- IOVA $13.60
- PRME $8.27
- Technical
- Relative Strength Index (RSI)
- IOVA 43.38
- PRME 40.43
- Support Level
- IOVA $3.02
- PRME $1.30
- Resistance Level
- IOVA $3.73
- PRME $1.83
- Average True Range (ATR)
- IOVA 0.25
- PRME 0.19
- MACD
- IOVA 0.01
- PRME -0.00
- Stochastic Oscillator
- IOVA 25.33
- PRME 25.61
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.